

1.2 IN THE CLAIMS:

1. (Currently Amended) A recombinant adeno-associated viral vector comprising at least a first nucleic acid segment encoding a biologically-active mammalian Factor VII peptide, polypeptide or protein operably linked to at least a first promoter capable of expressing said segment in a mammalian host cell transformed with said vector.
- 2-7. (Cancelled)
8. (Currently Amended) The recombinant adeno-associated viral vector of claim 16, wherein said nucleic acid segment encodes a biologically-active mammalian Factor VII peptide, polypeptide or protein that comprises the sequence of any one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:15 or SEQ ID NO:17.
9. (Original) The recombinant adeno-associated viral vector of claim 1, wherein said nucleic acid segment encodes a biologically-active human Factor VII peptide, polypeptide or protein.
- 10.-15. (Cancelled)
16. (Currently Amended) The recombinant adeno-associated viral vector of claim 145, wherein said nucleic acid segment comprises the nucleotide sequence of any one of SEQ

ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11,
or SEQ ID NO:13.

17.-26. (Cancelled)

27. (Original) The recombinant adeno-associated viral vector of claim 1, wherein said nucleic acid segment encodes a biologically-active mammalian Factor VII polypeptide that is at least 85% identical to the amino acid sequence of any of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:15 or SEQ ID NO:17.

28. (Original) The recombinant adeno-associated viral vector of claim 27, wherein said nucleic acid segment encodes a biologically-active mammalian Factor VII polypeptide that is at least 90% identical to the amino acid sequence of any of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:15 or SEQ ID NO:17.

29. (Original) The recombinant adeno-associated viral vector of claim 28, wherein said nucleic acid segment encodes a biologically-active mammalian Factor VII polypeptide that is at least 95% identical to the amino acid sequence of any of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:15 or SEQ ID NO:17.

30. (Original) The recombinant adeno-associated viral vector of claim 29, wherein said nucleic acid segment encodes a biologically-active mammalian Factor VII polypeptide that is at least 98% identical to the amino acid sequence of any of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:15 or SEQ ID NO:17.
31. (Original) The recombinant adeno-associated viral vector of claim 1, wherein said nucleic acid segment encodes a biologically-active mammalian Factor VII polypeptide that is at least 85% identical to the amino acid sequence of SEQ ID NO:2.
32. (Original) The recombinant adeno-associated viral vector of claim 31, wherein said nucleic acid segment encodes a biologically-active mammalian Factor VII polypeptide that is at least 88% identical to the amino acid sequence of SEQ ID NO:2.
33. (Original) The recombinant adeno-associated viral vector of claim 32, wherein said nucleic acid segment encodes a biologically-active mammalian Factor VII polypeptide that is at least 91% identical to the amino acid sequence of SEQ ID NO:2.
34. (Original) The recombinant adeno-associated viral vector of claim 33, wherein said nucleic acid segment encodes a biologically-active mammalian Factor VII polypeptide that is at least 94% identical to the amino acid sequence of SEQ ID NO:2.

35. (Original) The recombinant adeno-associated viral vector of claim 34, wherein said nucleic acid segment encodes a biologically-active mammalian Factor VII polypeptide that is at least 97% identical to the amino acid sequence of SEQ ID NO:2.
36. (Original) The recombinant adeno-associated viral vector of claim 1, comprised within an adeno-associated viral particle.
37. (Cancelled)
38. (Original) The recombinant adeno-associated viral vector of claim 1, comprised within an isolated mammalian host cell.
- 39.-40. (Cancelled)
41. (Original) A host cell comprising: (a) the recombinant adeno-associated viral vector of claim 1; (b) the virion of claim 39; or (c) the plurality of viral particles of claim 40.
- 42.-44. (Cancelled)
45. (Original) A composition comprising: (a) the recombinant adeno-associated viral vector of claim 1; (b) the virion of claim 39; (c) the plurality of viral particles of claim 40, or the host cell of claim 41.

46.-55. (Cancelled)

56. (Original) A method for providing an animal a biologically-active Factor VII peptide or polypeptide, said method comprising administering to said mammal: (a) the recombinant adeno-associated viral vector of claim 1; (b) the virion of claim 39; (c) the plurality of viral particles of claim 40; (c) the host cell of claim 41; or (d) the composition of claim 45, in an amount and for a time sufficient to provide said mammal with an effective amount of said biologically-active Factor VII peptide or polypeptide.

57. (Cancelled)

58. (Original) A method for treating or ameliorating the symptoms of a Factor VII polypeptide defect, deficiency or dysfunction in a mammal, said method comprising administering to said mammal: (a) the recombinant adeno-associated viral vector of claim 1; (b) the virion of claim 39; (c) the plurality of viral particles of claim 40; (c) the host cell of claim 41; or (d) the composition of claim 45, in an amount and for a time sufficient to treat or ameliorate the symptoms of said defect, deficiency or dysfunction in said mammal.

59. (Original) The method of claim 58, wherein said mammal has, is at risk for developing, or is diagnosed with hemophilia, a clotting deficiency, or a bleeding disorder.

60. (Original) A method for treating or ameliorating the symptoms of hemophilia in a mammal, said method comprising administering to said mammal: (a) the recombinant adeno-associated viral vector of claim 1; (b) the virion of claim 39; (c) the plurality of viral particles of claim 40; (c) the host cell of claim 41; or (d) the composition of claim 45, in an amount and for a time sufficient to treat or ameliorate the symptoms of hemophilia in said mammal.

61.-64. (Cancelled)

2. REMARKS

2.1 NATIONALIZATION

This application represents the U.S. national stage of International Patent Application PCT/US03/20746, filed June 30, 2003, which claims priority to United States Provisional Application Serial No. 60/392,725, filed June 28, 2002.

A copy of the International Application as filed is not required to satisfy 35 U.S.C. § 371(c)(2) as the application was filed in the United States Receiving Office. Nonetheless, for the Examiner's convenience, a copy of international application PCT/US03/20746 is enclosed.

2.2 STATUS OF THE CLAIMS

After according a U.S. filing date, and before calculating the filing fee, entry of the foregoing claim amendments is respectfully requested. These revisions are made to conform the claims to U.S. practice, and to even more clearly define the claimed invention. This voluntary amendment is submitted in an effort to reduce excess claims fees, and to expedite examination and allowance of claims directed to particular embodiments of the invention.

Claims 1-64 were present in the original PCT application as filed.

Claims 2-7, 10-15, 17-26, 37, 39-40, 42-44, 46-55, 57 and 61-64 have been canceled herein without prejudice and without disclaimer. Applicants expressly reserve the right to re-file these claims, or claims directed to the subject matter of these claims, at a later stage in prosecution, or in a divisional or other continuing application based upon the present application at any time during its pendency.

Claims 1, 8 and 16 have been amended herein.

No claims have been added.

Claims 1, 8, 9, 16, 27-36, 38, 41, 45, 56 and 58-60 are now pending in the case and ready for initial examination on the merits.

The present claims are fully supported by the specification and claims of the original international application and do not, in any way, contain new matter.

2.3 FORMAL DRAWINGS ARE PROVIDED

Applicants also submit herewith formal drawings (FIG. 1) on 1 sheet, and ask that they be accepted by the draftsman.

2.4 A SEQUENCE LISTING IN BOTH PAPER AND ELECTRONIC FORMATS ARE PROVIDED

Applicants also submit herewith the required sequence listing in both paper and electronic formats and ask that they be entered into the record prior to examination on the merits.

2.5 FORMALITIES AND SUMMARY

The national filing fee and claim fees are included herewith. Any omitted fees should be deducted from Williams, Morgan & Amerson Deposit Account No. 50-0786/4300.014300.